Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Brain Cancer
Datar Cancer Genetics obtains FDA breakthrough device designation for blood test to detect inaccessible brain tumors
A prospective, blinded study by London’s Imperial College researchers showed the TriNetra-Glio liquid biopsy test, which requires 15 mL of blood, can detect malignant brain tumors.
January 3, 2023
Foundation to present on genomic profiling at ESMO 2022
At the congress, which is being held in Paris September 9-13, Foundation Medicine will highlight the following:
September 6, 2022
Insightec to launch new trials of Exablate Neuro
One study will evaluate the use of Exablate Neuro to treat patients with primary non-small cell lung cancer that has metastasized to the brain in conjunction with Keytruda, a humanized antibody immunotherapy. Exablate Neuro could be used to open up the blood-brain barrier to make immunotherapy agents like Keytruda more effective.
March 9, 2022
Cancer mortality declined by 27% over past five decades
Mortality rates decreased "significantly" for 12 of the 15 top cancer sites analyzed, according to a team led by Tyler Kratzer from the American Cancer Society. The researchers also found greater mortality declines for certain cancers in particular years, such as lung cancer being 44% lower in 2019 compared with its peak rate in 1993.
November 11, 2021
Week in Review: NCI champions AI | Young adult genetic testing featured at AACR | Liquid biopsy classifies brain cancers
Dear LabPulse Member,
June 25, 2020
AI-driven DNA methylation liquid biopsy shows promise in brain and kidney cancer
The method -- called cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) -- has been developed for blood and other kinds of liquid specimens. Testing screens for abnormal methylation, whereas liquid biopsy tests typically look for mutations, the researchers explained.
June 23, 2020
NYU Langone launches genetic profiling of brain tumors
The services are based on epigenetic research on central nervous system tumors published by NYU Langone's pathologists with the German Cancer Research Center in Heidelberg (Capper et al, Nature, March 22, 2018, Vol. 555:7697, pp. 469-474). The researchers used DNA methylation to improve the accuracy of diagnosis for brain tumors, and the classifier is available online at no cost.
October 27, 2019
Crackdown on unwise lab tests | Blood test enhances lung cancer screening | Tumor mutational burden falls short
Dear LabPulse Member,
September 9, 2019
CAP offers guideline on molecular testing in brain cancer
CAP has drafted 13 recommendations related to testing for diffuse gliomas, with the guideline open for public comment through September 30. The draft recommendations include strong endorsements for IDH mutational testing in all diffuse gliomas and for MGMT promoter methylation testing in all cases of glioblastoma. CAP also included guidance on the management of patients with a 1p/19q codeletion.
September 9, 2019
Page 1 of 1
